TransCode sets 2026 annual meeting, proposal deadlines
TransCode Therapeutics, Inc. has scheduled its 2026 annual meeting of stockholders for July 2, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
TransCode Therapeutics, Inc. has scheduled its 2026 annual meeting of stockholders for July 2, 2026. Stockholders of record at the close of business on May 28, 2026 will be entitled to receive notice of, and vote at, the meeting.
Because this date is more than 30 days after the one-year anniversary of the 2025 annual meeting, the company is updating deadlines for stockholder proposals and director nominations. To be included in the proxy materials or otherwise properly brought before the meeting, proposals, nominations, and universal proxy notices must be delivered in writing to the Corporate Secretary at the Boston corporate address by 5:00 p.m. Eastern Time on June 11, 2026, and must also comply with Delaware law, SEC rules, and the company’s bylaws.
8-K Event Classification
Item 5.08 — Shareholder Director Nominations
1 item
Item 5.08
Shareholder Director Nominations
Governance
Shareholder nominations for board of directors under proxy access rules. Rarely used -- the underlying SEC rule was vacated.
Key Figures
2026 annual meeting date: July 2, 2026
Record date: May 28, 2026
Proposal deadline: June 11, 2026, 5:00 p.m. ET
+3 more
6 metrics
2026 annual meeting date
July 2, 2026
Scheduled date of 2026 annual meeting of stockholders
Record date
May 28, 2026
Close of business date determining who can vote at 2026 meeting
Proposal deadline
June 11, 2026, 5:00 p.m. ET
Cutoff for Rule 14a-8 stockholder proposals for 2026 meeting
Nomination notice deadline
June 11, 2026
Deadline for other director nominations and business notices
Universal proxy notice deadline
June 11, 2026
Deadline for Rule 14a-19 universal proxy solicitation notices
2025 annual meeting date
August 29, 2025
Prior annual meeting date used to assess >30-day change
Key Terms
Rule 14a-8, universal proxy rules, Rule 14a-19, record date, +1 more
5 terms
Rule 14a-8 regulatory
"Pursuant to Rule 14a-8 of the Exchange Act and the Company’s amended and restated bylaws"
Rule 14a-8 is a U.S. Securities and Exchange Commission regulation that lets eligible shareholders put proposals on a public company’s proxy ballot for an annual meeting, provided they meet basic ownership and filing requirements. It matters to investors because it creates a formal way to raise governance or strategic issues and force a company-wide vote—like getting an item onto the agenda of a neighborhood association meeting once you’ve lived there long enough—so shareholders can push for change or influence management decisions.
universal proxy rules regulatory
"In addition, to comply with the SEC’s universal proxy rules, stockholders who intend to solicit proxies"
Universal proxy rules require that when shareholders vote to elect directors in a contested election, the proxy card mailed to investors can include candidates nominated by both the company and dissident shareholders, letting investors mix and match their choices on a single ballot. This matters to investors because it makes their vote more flexible and easier to use, like replacing separate lists with one common ballot, which can influence who controls the board and the company’s future direction.
Rule 14a-19 regulatory
"setting forth the information required by Rule 14a-19 under the Exchange Act no later than the close of business"
Rule 14a-19 is a U.S. Securities and Exchange Commission rule that governs how independent proxy advisory firms produce and distribute voting recommendations for shareholders. It requires these advisers to provide companies with notice of their recommendations and a chance to respond, and to disclose certain conflicts; think of it as a referee ensuring both sides see a game plan before fans cast votes. Investors care because proxy advisers influence voting outcomes and corporate governance, so the rule affects transparency, potential bias, and the reliability of guidance that many investors rely on when voting shares.
record date financial
"set the close of business on May 28, 2026, as the record date for the determination of stockholders"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
amended and restated bylaws regulatory
"pursuant to Rule 14a-8 of the Exchange Act and the Company’s amended and restated bylaws"
A company’s amended and restated bylaws are its internal rulebook rewritten to include all changes in one updated document, replacing the old bylaws. For investors, this matters because the bylaws set how the board, shareholders and officers make decisions, hold votes and handle disputes; a new consolidated version can change voting rights, control mechanisms or procedures that affect corporate governance and the value or risk of an investment.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When is TransCode Therapeutics (RNAZ) holding its 2026 annual meeting?
TransCode Therapeutics plans to hold its 2026 annual meeting of stockholders on July 2, 2026. Details on the exact time and location will appear in the company’s definitive proxy statement on Schedule 14A for the 2026 annual meeting.
What is the record date for TransCode Therapeutics (RNAZ) 2026 annual meeting?
The record date for the 2026 annual meeting is the close of business on May 28, 2026. Stockholders who hold shares on that date will be entitled to receive notice of, and vote at, the 2026 annual meeting.
What is the deadline to submit stockholder proposals for TransCode Therapeutics (RNAZ) 2026 meeting?
Stockholder proposals for inclusion in the 2026 proxy statement must be delivered in writing to the Corporate Secretary by 5:00 p.m. Eastern Time on June 11, 2026, and must comply with Rule 14a-8, Delaware law, SEC rules, and the bylaws.
How can stockholders nominate directors at TransCode Therapeutics (RNAZ) 2026 annual meeting?
To nominate directors outside Rule 14a-8, stockholders must deliver proper written notice to the Corporate Secretary at the Boston corporate address by the close of business on June 11, 2026, following the procedures in the company’s amended and restated bylaws.
What are the universal proxy notice requirements for TransCode Therapeutics (RNAZ)?
Stockholders intending to solicit proxies for their own director nominees must provide written notice under Rule 14a-19 to the Corporate Secretary by the close of business on June 11, 2026, including all information that Rule 14a-19 under the Exchange Act requires.
Why did TransCode Therapeutics (RNAZ) update its proposal deadlines for 2026?
The 2026 annual meeting date of July 2, 2026 falls more than 30 days after the one-year anniversary of the August 29, 2025 annual meeting. This change triggers updated notice and proposal deadlines under Rule 14a-5(f) of the Exchange Act.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates